RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79
CG Oncology, Inc.
CG Oncology, Inc. CGON | 0.00 |
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:
CGON) with a Outperform and lowers the price target from $81 to $79.